Nonapeptide isolated from cerebral venous blood during induced slow-wave sleep
DSIP
Delta Sleep-Inducing Peptide — a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, WAGGDASGE) isolated from the cerebral venous blood of rabbits during electrical slow-wave sleep induction
Overview
DSIP is one of the peptide catalog's genuine mysteries. Its 1977 discovery story is unusually cinematic: Marcel Monnier and Guido Schoenenberger at the University of Basel subjected rabbits to electrical thalamic stimulation that induced slow-wave (delta) sleep, drew cerebral venous blood from those animals, and demonstrated that transferring the blood to naive rabbits induced sleep in them. The active fraction was purified into a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) and named 'delta sleep-inducing peptide' for its purported EEG signature. That founding observation is compelling in a way that many peptide discovery stories are not.
Fifty years later, the science has become both more elaborate and less conclusive. DSIP has been shown to cross the blood-brain barrier and to modulate GABAergic, serotonergic, monoaminergic and opioid-system tone. Small human clinical studies in the 1980s and 1990s — Kastin, Graf and colleagues — reported signals in chronic pain, narcolepsy, and opioid withdrawal, but the trials were small, uncontrolled by modern standards, and produced mixed results. Mechanistic characterisation has continued into the 2010s (Kovalzon and others in the Russian tradition), but no unifying receptor-pharmacology has emerged. Whether DSIP actually induces slow-wave sleep in humans — the founding hypothesis — has never been definitively established under contemporary ICH-GCP standards.
No regulator has ever approved DSIP for any indication. It has no approved-drug identity. It circulates in the peptide-therapy market as a grey-market sleep peptide, typically as a lyophilized vial reconstituted for subcutaneous injection before bed. Consumer discussions of it often cite the founding delta-wave observation as if it settled the case; the primary literature is considerably more measured. Selank (see related compound) covers similar sleep-architecture and cortisol-modulation territory with a more established mechanism and a Russian approved-drug identity, and is a reasonable comparator for readers considering the DSIP space.
Quick Facts & Evidence
- Category
- Nonapeptide isolated from cerebral venous blood during induced slow-wave sleep
- Research area
- Sleep-related neuropeptide
- Most studied for
- Slow-wave sleep induction (the founding hypothesis)
- Chronic pain (historical small human studies)
- Opioid withdrawal (historical small human studies)
- Cortisol rhythm modulation
- Narcolepsy (historical exploration)
- Clinical status
- Research use only — no approved clinical indication
- Human evidence
- Preclinical Evidence
- Regulatory status
- Not approved by FDA, EMA or MHRA
Preclinical Evidence
Data are from animal models, cell studies, or anecdotal community reports. No controlled human evidence.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format
This page covers the RUO lyophilized DSIP vial reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention.
DSIP research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 5 mg |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 2.0 mL |
| Final concentration | 2.5 mg/mL |
| How it's given | Subcutaneous injection |
| Research dose | 100–300 mcg (0.1–0.3 mg) |
| Timing | 30–60 minutes before bed |
| Frequency | Nightly during an active cycle; typically 8–12 weeks per phase |
Reported Dosing
The practitioner-reference research protocol for DSIP is 100–300 mcg per subcutaneous injection, 30–60 minutes before bed, nightly during an active 8–12 week cycle. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 0.1–0.3 mg (100–300 mcg) | Nightly, 30–60 min pre-bed, subcutaneous | 8–12 weeks during a sleep-optimisation phase | 0.04–0.12 mL at 2.5 mg/mL |
Why protocols vary
DSIP's pharmacology is time-of-day dependent — the effect aligns with the natural nocturnal delta-wave window rather than acting across the day. Pre-bed timing keeps the pharmacologic pulse aligned with when the sleep architecture is most amenable.
The 8–12 week phase length matches typical sleep-optimisation cycles; the DSIP mechanism is incompletely characterised and no evidence exists for chronic multi-year continuous use.
Preparing the Solution
Turning the freeze-dried powder into a measurable liquid.
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 5 mg vial
Diluent: 2.0 mL bacteriostatic water
Final concentration: 2.5 mg/mL
Vial and volume from the practitioner reference; concentration calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
2mL
Resulting concentration
2.5 mg/mL
Equivalent volume
The reported research amount of 0.10–0.30 mg is contained within
0.04–0.12mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 5 mg ÷ 2 mL = 2.5 mg/mL
- Bacteriostatic water to match the documented concentration
- 5 mg ÷ 2.5 mg/mL = 2 mL
- Equivalent volume at this concentration
- 0.10–0.30 mg ÷ 2.5 mg/mL = 0.04–0.12 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner referenceResearch-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, nightly 30–60 minutes before bed
Documented in the practitioner reference · Research-practitioner guide
Why this method
DSIP is a 9-amino-acid neuropeptide; the subcutaneous route delivers it into circulation without the gastrointestinal degradation that would break the molecule down.
Pre-bed timing aligns the pharmacologic pulse with the body's natural onset of delta-wave sleep architecture.
Injection sites reported
- Abdomen (rotate sites)
- Front of the thigh
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light
- Do not freeze
General RUO practice · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within 7–10 days
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises standard RUO peptide handling. Grey-market DSIP identity and mass should be verified from the dispensing source before use.
Common Cycle
The practitioner reference frames DSIP as 8–12 week sleep-optimisation phases rather than continuous chronic use.
- Cycle Length
- 8–12 weeks per phase
- Break Before the Next Cycle
- No formally established cycle
- What the Research Shows
- No large controlled human trial has evaluated repeat-cycle safety for DSIP
Documented in the practitioner reference · Research-practitioner guide
The DSIP mechanism is incompletely characterised; the practitioner-reference cycle length reflects the limited long-term human evidence.
Compound Overview
Current areas of research
Effects reported in small historical human studies and grey-market use.
- Potential slow-wave sleep effects (founding hypothesis; incompletely validated in humans)
- Historic signals in chronic pain and opioid withdrawal (mixed evidence)
- Cortisol rhythm modulation
- Reported to lack morning grogginess or cognitive impairment (grey-market experience)
Mechanism of action
DSIP is one of the peptide catalog's genuine mysteries. Its 1977 discovery story is unusually cinematic: Marcel Monnier and Guido Schoenenberger at the University of Basel subjected rabbits to electrical thalamic stimulation that induced slow-wave (delta) sleep, drew cerebral venous blood from those animals, and demonstrated that transferring the blood to naive rabbits induced sleep in them. The active fraction was purified into a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) and named 'delta sleep-inducing peptide' for its purported EEG signature. That founding observation is compelling in a way that many peptide discovery stories are not.
Fifty years later, the science has become both more elaborate and less conclusive. DSIP has been shown to cross the blood-brain barrier and to modulate GABAergic, serotonergic, monoaminergic and opioid-system tone. Small human clinical studies in the 1980s and 1990s — Kastin, Graf and colleagues — reported signals in chronic pain, narcolepsy, and opioid withdrawal, but the trials were small, uncontrolled by modern standards, and produced mixed results. Mechanistic characterisation has continued into the 2010s (Kovalzon and others in the Russian tradition), but no unifying receptor-pharmacology has emerged. Whether DSIP actually induces slow-wave sleep in humans — the founding hypothesis — has never been definitively established under contemporary ICH-GCP standards.
No regulator has ever approved DSIP for any indication. It has no approved-drug identity. It circulates in the peptide-therapy market as a grey-market sleep peptide, typically as a lyophilized vial reconstituted for subcutaneous injection before bed. Consumer discussions of it often cite the founding delta-wave observation as if it settled the case; the primary literature is considerably more measured. Selank (see related compound) covers similar sleep-architecture and cortisol-modulation territory with a more established mechanism and a Russian approved-drug identity, and is a reasonable comparator for readers considering the DSIP space.
- Nonapeptide isolated in 1977 from cerebral venous blood of rabbits during electrically-induced slow-wave sleep — one of the peptide catalog's most cinematic discovery stories
- Polypharmacological CNS profile without a single dominant receptor; mechanism remains incompletely characterised
- No approved product anywhere; primary literature is dominated by small historical human studies and mechanistic characterisation
Human research
The founding discovery paper is Monnier, Schoenenberger et al. Experientia 1977, reporting the isolation of the active fraction from cerebral venous blood of rabbits during electrically-induced slow-wave sleep. Schoenenberger's 1984 review consolidated the early mechanistic thinking.
Kastin, Graf and colleagues carried out most of the small human clinical trials of DSIP in the 1980s — chronic pain, narcolepsy, opioid withdrawal. Results were mixed and never triggered a phase-3 programme.
Kovalzon (Russian sleep laboratory) has continued mechanistic characterisation of DSIP into the 2010s. His work is a good entry point into the modern DSIP literature for readers who want to understand the compound's current research standing.
Monnier & Schoenenberger 1977
The founding discovery paper. Isolation of DSIP from cerebral venous blood of rabbits during electrically-induced slow-wave sleep. One of the peptide catalog's most cinematic discovery observations.
Schoenenberger 1984 review
Consolidating review of the DSIP literature through the mid-1980s. Sets out the founding mechanistic framework and the small human clinical evidence at that point.
Graf & Kastin 1984
One of the small human clinical studies of DSIP by the Kastin group in the 1980s. Representative of the mixed-results historical human evidence base.
Kovalzon 2013
Modern mechanistic characterisation of DSIP by Kovalzon's Russian sleep laboratory. A useful entry point into the compound's current research standing.
DSIP has never been an approved therapeutic anywhere. Its scientific interest is real — the 1977 discovery story is genuinely striking — but that interest has not translated into either a validated human clinical benefit or a regulatory approval in the intervening fifty years.
Selank (Russian regulator peptide, see related compound page) covers similar sleep-architecture and cortisol-modulation territory with a more established mechanism and Russian regulatory identity, and is a reasonable comparator for readers considering the DSIP space.
Safety considerations
Adverse events reported in small historical studies.
- Transient headache, nausea, vertigo in IV studies
- Limited grey-market experience — long-term safety not characterised
No approved-label warnings exist. Considerations below draw on the compound's pharmacology.
- Active severe psychiatric conditions warrant caution
- Pregnancy and breastfeeding — no adequate data
- Grey-market provenance without verifiable identity
Monitoring
- Injection-site reactions
- Sleep quality response
- Any unexpected CNS effect
Frequently asked questions
Does DSIP actually induce slow-wave sleep in humans?
This is genuinely uncertain. The founding 1977 discovery was in rabbits during electrical thalamic stimulation, and subsequent small human studies produced mixed signals. No ICH-GCP-standard randomised placebo-controlled human trial has definitively established the effect. Consumer sources treat the founding observation as if it settled the case; the primary literature is more measured.
Is DSIP an approved medicine?
No. It has never been approved by any regulator for any indication, in any country. It circulates as a grey-market peptide with no established clinical framework.
What is the mechanism?
Polypharmacological rather than tied to a single receptor. Studies have documented GABAergic, serotonergic, monoaminergic and opioid-system modulation. No unifying receptor-pharmacology has emerged in fifty years of research. That mechanistic ambiguity is a real feature of the compound's story.
How does DSIP compare to Selank?
Selank has a more established mechanism, a Russian approved-drug identity, and a clinical evidence base in generalised anxiety disorder including cortisol modulation and sleep-architecture effects. DSIP has a more evocative discovery story but no approved identity and less contemporary clinical characterisation. For readers considering the sleep/cortisol modulation space, Selank is often a more evidence-supported comparator.
References
- [1]
Isolation of a delta sleep-inducing peptide (DSIP) from cerebral venous blood of rabbits during electrically induced slow-wave sleep — Monnier M, Schoenenberger GA, Experientia (1977)
- [2]
Delta sleep-inducing peptide (DSIP) — a consolidating review of the founding discovery and early clinical work — Schoenenberger GA, European Neurology (1984)
- [3]
Modern mechanistic characterisation of DSIP — Kovalzon Russian sleep laboratory — Kovalzon VM, Neurochemical Journal (2013)
- [4]
Delta sleep-inducing peptide human clinical characterisation — Kastin group historic studies — Graf MV, Kastin AJ, Peptides (1984)
- [5]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.
Related on Healthy Mango
Categories